


Imidazopyrazine Derivatives As Inhibitors of mTOR

Gerard Rosse*

Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States, and Adjunct Associate Professor, Department of Pharmacology and Physiology, Drexel University, College of Medicine, New College Building, 245 North 15th Street, Philadelphia, Pennsylvania 19102, United States



Johnson, S. C.; Rabinovitch, P. S.; Kaeberlein, M. mTOR is a key modulator of aging and age-related disease. *Nature* **2013**, 493 (7432) 338-345.

 Received:
 April 11, 2013

 Published:
 April 18, 2013



ONS © 2013 American Chemical Society

Biological Assay:

Compound inhibitory activity was evaluated using an HTRF mTOR enzyme assay. Inhibition of mTORC1 and mTORC2 was measured using an immunofluorescent cell-based assay. Inhibition of mTORC1 activity was measured by the reduction of the level of phosphorylated 4E-BP1Thr37/46 (p4E-BP1Thr37/46). Inhibition of mTORC2 activity was measured by the reduction of the level of phosphorylated AKTSer473 (pAKTSer473).

Pharmacological Data:

Compound	pAKTSer473	p4E-BP1Thr37/46
	(IC ₅₀ nM)	(IC ₅₀ nM)
1	1-100	100-1000
2	-	-
3	100-1000	100-1000
4	1000-10000	1000-10000
5	1135	1863
6	1000-10000	>10000
7	>10000	>10000

Synthesis:

Preparation of 7 compounds.

AUTHOR INFORMATION

Corresponding Author

*E-mail: grosse@dartneuroscience.com.

Notes

The authors declare no competing financial interest.

Patent Highlight